References
- Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest 2007;117:850–8.
- Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990;322:1617–21.
- Elghetany MT, Banki K. Erythrocytic disorders. In: McPherson RA, Pincus MR, eds. Henry’s clinical diagnosis and management by laboratory methods. 21st ed. Philadelphia, PA: Saunders Elsevier, 2007:504–44.
- Ogedegbe HO. Sickle cell disease: an overview. Lab Med 2002;33:515–43.
- Ohene-Frempong K. Indications for red cell transfusion in sickle cell disease. Semin Hematol 2001;38:5–13.
- Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986;314:1593–9.
- Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle cell disease. Cooperative study of sickle cell disease. Pediatrics 1989;84:500–8.
- Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 1995;86:776–83.
- Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease-life expectancy and risk factors for early death. N Engl J Med 1994;330:1639–44.
- Telen MJ. Role of adhesion molecules and vascular endothelium in the pathogenesis of sickle cell disease. Hematol Am Soc Hematol Educ Program 2007;84-90.
- Kupyers FA. Membrane lipid alterations in hemoglobinopathies. Hematology Am Soc Hematol Educ Program 2007;68-73.
- Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998;91:4216–23.
- Wang WC. The pathophysiology, prevention, and treatment of stroke in sickle cell disease. Curr Opin Hematol 2007;14:191–7.
- Adams RJ, McKie VC, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 1992;326:605–10.
- Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5–11.
- Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials 1998;19:110–29.
- Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000;342:1855–65.
- Sakhalkar VS, Rao SP, Weedon J, Miller ST. Elevated plasma sVCAM-1 levels in children with sickle cell disease: impact of chronic transfusion therapy. Am J Hematol 2004;76:57–60.
- Styles LA, Abboud M, Larkin S, Lo M, Kuypers FA. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol 2007;136:343–4.
- Claster S, Vichinsky EP. Managing sickle cell disease. BMJ 2003;327:1151–5.
- Platt O, Thorington B, Brambilla D, et al. Pain in sickle cell disease. N Engl J Med 1991;325:11–16.
- Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645–51.
- Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317–22.
- Ware RE, Zimmerman SA, Shultz WH. Hydroxyurea as an alternative to blood transfusion for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999;94:3022–6.
- Zimmerman SA, Schultz WH, Burgett S, et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007;110:1043–7.
- Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003;101:2137–43.
- Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007;110:2749–56.
- Woodard P, Jeng M, Handgretinger R, et al. Summary of symposium: the future of stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol 2002;34:512–17.
- Josephson CD, Lu LL, Killyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfus Med Rev 2007;21:118–33.
- Koshy M, Burd L, Wallace D, et al. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. N Engl J Med 1988;319:1447–52.
- Rackoff WR, Ohene-Frempong K, Month S, et al. Neurologic events after partial exchange transfusion for priapism in sickle cell disease. J Pediatr 1992;120:882–5.
- Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med 1995;333:206–13.
- Buck J, Casbard A, Llewelyn C, Johnson T, Davies SC, Williamson LM. Preoperative transfusion in sickle cell disease: a survey of practice in England. Eur J Haematol 2005;75:14–21.
- Platt OS. The acute chest syndrome of sickle cell disease. N Engl J Med 2000;342:1904–7.
- Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769–78.
- Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001;41:1086–92.
- Osby M, Shulman IA. Phenotype matching of donor red blood cells units for non alloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med 2005;129:190–3.
- Afenyi-Annan A, Brecher ME. Pre-transfusion phenotype matching for sickle cell disease patients. Transfusion 2005;44:619–20.
- Ness PM. To match or not to match: the question for chronically transfused patients with sickle cell anemia. Transfusion 1994;34:558–60.
- Hillyer KL, Hare VW, Josephson CD, et al. Partners for life: the transfused program for patients with sickle cell disease offered at the American Red Cross Blood Services, Southern Region, Atlanta, Georgia. Immunohematology 2006;22:108–11.
- Brecher ME. Technical Manual. 15th ed. Bethesda, MD: American Association of Blood Banks, 2005.
- King KE, Shirey RS, Lenkiewica MW, et al. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients’ red cells. Transfusion 1997;37:376–81.
- Petz LD, Calhoun L, Shulman IA, et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion 1997;37:382–92.
- Win N, Yeghen T, Needs, et al. Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease. Hematology 2004;9:433–6.
- Porter JB. Concepts and goals in the management oftransfusional iron overload. Am J Hematol 2007;82:1136–9.
- Blumberg N, Heal JM, Gettings KF. Leukoreduction of red cell transfusion is associated with a decreased incidence of red cell alloimmunization. Transfusion 2003;43:945–52.
- Mayo Clinic. Sickle cell anemia. Available at: http://www.mayoclinic.com/health/sickle-cell-anemia/DS00324. Accessed July 20, 2009.
- Sickle Cell Disease Association of America, Inc. Available at: http://www.sicklecelldisease.org/. Accessed July 20, 2009.
- March of Dimes. Available at: http://www.marchofdimes.com/. Accessed July 20, 2009.
- Lab Tests On Line. Available at: http://www.labtestsonline.org/. Accessed July 20, 2009.
- Susan D. Roseff, MD, Medical Director, Transfusion Medicine, Professor, Virginia Commonwealth University, Department of Pathology, PO Box 980662, Richmond VA 23298-0662.